Fresenius Medical Care AG (NYSE:FMS)‘s stock had its “buy” rating reiterated by investment analysts at Goldman Sachs Group Inc. in a research report issued on Wednesday.

Other analysts have also issued research reports about the stock. Royal Bank Of Canada reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 24th. Jefferies Group raised shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a report on Friday, July 8th. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG in a report on Thursday, August 4th. Berenberg Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday, August 9th. Finally, Citigroup Inc. raised shares of Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $42.50.

Analyst Recommendations for Fresenius Medical Care AG (NYSE:FMS)

Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 0.73% during trading on Wednesday, reaching $44.35. The company had a trading volume of 144,121 shares. Fresenius Medical Care AG has a 12-month low of $38.11 and a 12-month high of $47.52. The firm has a 50-day moving average of $45.22 and a 200-day moving average of $43.76. The company has a market cap of $27.12 billion, a P/E ratio of 24.58 and a beta of 0.53.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fresenius-medical-care-ag-fms-receives-buy-rating-from-goldman-sachs-group-inc.html

Fresenius Medical Care AG (NYSE:FMS) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.04. The firm earned $4.42 billion during the quarter, compared to analysts’ expectations of $4.54 billion. Fresenius Medical Care AG had a net margin of 6.40% and a return on equity of 9.66%. On average, equities research analysts anticipate that Fresenius Medical Care AG will post $2.01 EPS for the current year.

Several hedge funds have recently modified their holdings of FMS. JPMorgan Chase & Co. raised its stake in shares of Fresenius Medical Care AG by 1.5% in the first quarter. JPMorgan Chase & Co. now owns 134,551 shares of the company’s stock worth $5,930,000 after buying an additional 1,950 shares in the last quarter. Rothschild Asset Management Inc. bought a new stake in shares of Fresenius Medical Care AG during the second quarter worth $340,000. Envestnet Asset Management Inc. raised its stake in shares of Fresenius Medical Care AG by 22.6% in the first quarter. Envestnet Asset Management Inc. now owns 159,239 shares of the company’s stock worth $7,019,000 after buying an additional 29,368 shares in the last quarter. Mariner Wealth Advisors LLC bought a new stake in shares of Fresenius Medical Care AG during the first quarter worth $331,000. Finally, Wrapmanager Inc. bought a new stake in shares of Fresenius Medical Care AG during the first quarter worth $295,000. 2.33% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care AG

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.